Pharmaceuticals

Sydnexis's eye drop trial shows high efficacy in children 3-12, positioning it as a potential first-of-its-kind FDA-approved drug for myopia.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

Ephicacy appoints biometrics SVP Jamie Powers and India Head Tyagi Swaminathan in a strategic push to dominate advanced clinical trial analytics.

A key preclinical success in a $570M partnership advances a novel therapy designed to reset the immune system for patients with lupus, MS, and arthritis.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

A major chemical firm is raising prices, revealing how Red Sea disruptions and market volatility directly impact costs for pharma, personal care, and more.

With a new grant, Tessera Therapeutics is advancing its novel Gene Writing platform to engineer a scalable, single-shot cure for HIV. But can it work?

With major expansions in the US and Europe, Cambrex aims to lead the high-stakes race for specialized API production, targeting next-generation therapies.

A major labor dispute at the world's top drug manufacturer threatens global supply chains, with a union pointing to deep-seated governance issues at Samsung.

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

A top university and a global clinical research firm unite to slash drug development timelines, aiming to bring innovative therapies to patients faster.

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

RenovoRx sets a key update call, juggling early RenovoCath device sales with its pivotal Phase III pancreatic cancer trial, a beacon for patients.

Biotech firm Ribo Life Science reveals a new platform targeting the kidney, heart, and fat tissue, signaling a major shift for RNA-based medicines.

An influential guidelines update expands options for a tough-to-treat bladder cancer, giving patients access to a novel gene therapy beyond its FDA label.

Curia announces major upgrades to its UK sterile manufacturing and US biologics platforms, a strategic move to accelerate drug development timelines.

A new oral drug is being tested with existing therapies, offering a two-pronged attack on the glycogen buildup that defines this debilitating rare disease.

The National Bleeding Disorders Foundation taps celebrity power for a live event, aiming to spotlight underdiagnosed conditions and transform advocacy.